Comorbidities in patients with chronic obstructive lung disease and COVID-19 in Almaty (Kazakhstan Republic)

2022

Full text Open access: Hybrid Metadata (CSL-JSON)
DOI 10.18093/0869-0189-2022-32-6-923-926
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

SARS-CoV-2 (Severe Acute Respiratory Syndrome-related CoronaVirus 2) infection is characterized by multi-comorbidity, which increases the severity of the disease. The aim of the study was to identify the relationship between the length of stay in the hospital and the comorbidity and the severity of lung damage. Methods. 72 patients with COVID-19 (COronaVIrus Disease 2019) infection were studied, including 33 women and 39 men who were treated in the city hospitals. The average age was 67.4 ± 12.02 years. The SARS-CoV-2 RNA virus was identified by PCR in 46 (63.8%) patients. Results. The most common comorbidities in chronic obstructive pulmonary disease (COPD) patients with COVID-19 included arterial hypertension (in 32%), coronary artery disease (17%), and type 2 diabetes (10%). The majority of patients (48.7%) had the CT II stage. The total proportion of patients with an advanced damage (corresponding to CT III - IV) was 36.2%. Mean hospitalization length was 13.8 ± 7.9 days. Conclusion. COPD patients with COVID-19 infection included a significant percentage of patients with arterial hypertension, which required additional treatment.